$OCUP News

Last published 2y ago

2y agoOCUPThe RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsPR NewswireThe RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus...
2y agoOCUPOcuphire Pharma Announces Acquisition of Opus GeneticsGlobeNewswireAcquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual
2y agoOCUPOcuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in OphthalmologyGlobeNewswireFARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies
2y agoOCUPUPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaGlobeNewswireTop-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery
2y agoOCUPOcuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaGlobeNewswireTop-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery
2y agoOCUPOcuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate UpdateGlobeNewswireVEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with
2y agoOCUPOcuphire Pharma to Present at Two Investor Conferences in AugustGlobeNewswireFARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
2y agoOCUPOcuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in JulyGlobeNewswireCEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July
2y agoOCUPOcuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in JuneGlobeNewswireFARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment
2y agoOCUP VTRSOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate UpdateGlobeNewswireFARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of
2y agoOCUPOcuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual MeetingGlobeNewswireFARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal
2y agoOCUPOcuphire Pharma to Present at the Aegis Virtual ConferenceGlobeNewswireFARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and
2y agoOCUPOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingGlobeNewswireFARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of
2y agoOCUPFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryGlobeNewswireLYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a
2y agoOCUP VTRSOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisGlobeNewswireFARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of
2y agoOCUPOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate UpdateGlobeNewswireFARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the
2y agoOCUPOcuphire Pharma to Present in the BIO CEO & Investor ConferenceGlobeNewswireFARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing
2y agoOCUPOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
2y agoOCUPOcuphire Pharma Strengthens Leadership Team with Key AppointmentsGlobeNewswireAsh Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire
2y agoOCUPOcuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 ConferenceGlobeNewswireFARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
2y agoOCUPOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
2y agoOCUPOcuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light ConditionsGlobeNewswireFARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
2y agoOCUPOcuphire Pharma, Inc. (OCUP) Ocuphire Pharma Corporate Update Call (Transcript)Earnings Call Transcripts
2y agoOCUPOcuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIIIGlobeNewswireFARMINGTON HILLS, Mich., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
2y agoOCUPOcuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
2y agoOCUPOcuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating OfficerGlobeNewswireFARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
2y agoOCUPOcuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate UpdateGlobeNewswireSuccessful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2 Phase 3
3y agoOCUPOcuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic RetinopathyGlobeNewswireAgreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score Company Plans to Submit a Special Protocol Assessment (SPA) APX3330 has the Potential to be the
3y agoOCUPOcuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUPOcuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and DirectorGlobeNewswireFARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUPOcuphire Pharma to Present at AAO 2023 and Eyecelerator Retina ShowcaseGlobeNewswireFARMINGTON HILLS, Mich., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUPOcuphire Pharma to Present at Euretina and Retina Society Conferences in OctoberGlobeNewswireFARMINGTON HILLS, Mich., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUP VTRSOcuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) AgentsGlobeNewswireFARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing
3y agoOCUP VTRSViatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) AgentsPR NewswireRYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 PITTSBURGH, and FARMINGTON HILLS, Mich., Sept. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company,
3y agoOCUPOcuphire Pharma to Participate in Three Upcoming Investment Bank ConferencesGlobeNewswireFARMINGTON HILLS, Mich., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUPOcuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in SeptemberGlobeNewswireFARMINGTON HILLS, Mich., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUPAbstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer SymposiumGlobeNewswireFARMINGTON HILLS, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUPOcuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate UpdateGlobeNewswireEnd-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Million Expected to Fund Operations into 2025 Nyxol RM PDUFA date September 28, 2023;
3y agoOCUPOcuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in AugustGlobeNewswireFARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUPOcuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFARMINGTON HILLS, Mich., July 10, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent
3y agoOCUPOcuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual ConferenceGlobeNewswireFARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies
3y agoOCUPOcuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual ConferenceGlobeNewswireFARMINGTON HILLS, Mich., June 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the
3y agoOCUPOcuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023GlobeNewswireFARMINGTON HILLS, Mich., June 12, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the
3y agoOCUPOcuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate UpdateGlobeNewswireEnd-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR) PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced
3y agoOCUPOcuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and EyeceleratorGlobeNewswireFARMINGTON HILLS, Mich., May 02, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment
3y agoOCUPOcuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical ProgramsGlobeNewswirePDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval Oral APX3330 End of Phase 2 Meeting with FDA
3y agoOCUPOcuphire Appoints Rick Rodgers as Interim Chief Executive OfficerGlobeNewswireFARMINGTON HILLS, Mich., April 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the
3y agoOCUP VTRSOcuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate UpdateGlobeNewswireFinancial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025 PDUFA Date of September 28, 2023 Set for Nyxol® in its First
3y agoOCUPOcuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual MeetingGlobeNewswireOral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients Results from Phase 3 LYNX-1 Trial of Nyxol® in Dim Light Vision Disturbance to be Presented for the
3y agoOCUPOcuphire Announces APX3330 Phase 2 Data Presentations at Retina MeetingsGlobeNewswireTopline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting Topline Data from ZETA-1 Accepted for